rebeccamycin (BioDeep_00000182872)
human metabolite blood metabolite
代谢物信息卡片
化学式: C27H21Cl2N3O7 (569.0756496)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COC1C(O)C(O)C(OC1CO)N1C2=C(C3=C1C(Cl)=CC=C3)C1=C(C(=O)NC1=O)C1=C2NC2=C(Cl)C=CC=C12
InChI: InChI=1S/C27H21Cl2N3O7/c1-38-24-13(8-33)39-27(23(35)22(24)34)32-20-10(5-3-7-12(20)29)15-17-16(25(36)31-26(17)37)14-9-4-2-6-11(28)18(9)30-19(14)21(15)32/h2-7,13,22-24,27,30,33-35H,8H2,1H3,(H,31,36,37)
描述信息
同义名列表
3 个代谢物同义名
5,21-dichloro-23-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4,6,8,11(15),17(22),18,20-nonaene-12,14-dione; 5,21-Dichloro-3-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione; Rebeccamycin
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Fengling Cui, Lixia Qin, Guisheng Zhang, Xiaobing Liu, Xiaojun Yao, Beilei Lei. A concise approach to 1,11-didechloro-6-methyl-4'-O-demethyl rebeccamycin and its binding to human serum albumin: fluorescence spectroscopy and molecular modeling method.
Bioorganic & medicinal chemistry.
2008 Aug; 16(16):7615-21. doi:
10.1016/j.bmc.2008.07.017. [PMID: 18653350] - Gautam Borthakur, Yesid Alvarado, Farhad Ravandi-Kashani, Jorge Cortes, Zeev Estrov, Stefan Faderl, Percy Ivy, Carlos Bueso-Ramos, B Nebiyou Bekele, Francis Giles. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.
Cancer.
2008 Jul; 113(2):360-6. doi:
10.1002/cncr.23559. [PMID: 18473351] - Stacey L Berg, Alexander Aleksic, Leticia McGuffey, Robert Dauser, Jed Nuchtern, Bruce Bernacky, Susan M Blaney. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates.
Cancer chemotherapy and pharmacology.
2004 Aug; 54(2):127-30. doi:
10.1007/s00280-004-0787-0. [PMID: 15150671] - Maha Hussain, Ulka Vaishampayan, Lance K Heilbrun, Vikash Jain, Patricia M LoRusso, Percy Ivy, Lawrence Flaherty. A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer.
Investigational new drugs.
2003 Nov; 21(4):465-71. doi:
10.1023/a:1026259503954. [PMID: 14586215] - Jean-François Goossens, Jérôme Kluza, Hervé Vezin, Mustapha Kouach, Gilbert Briand, Brigitte Baldeyrou, Nicole Wattez, Christian Bailly. Plasma stability of two glycosyl indolocarbazole antitumor agents.
Biochemical pharmacology.
2003 Jan; 65(1):25-34. doi:
10.1016/s0006-2952(02)01418-1. [PMID: 12473375] - J F Goossens, J P Hénichart, F Anizon, M Prudhomme, C Dugave, J Riou, C Bailly. Cellular uptake and interaction with purified membranes of rebeccamycin derivatives.
European journal of pharmacology.
2000 Feb; 389(2-3):141-6. doi:
10.1016/s0014-2999(99)00895-x. [PMID: 10688977]